BMS and J&J first linked together in 2018 to develop factor X1a inhibitors as anti-coagulants. The three Phase III Librexia ...

Bayer has let go of about 13,500 employees, including around 5,000 managers, since implementing a new operating model in ...

Merck has made several big-ticket deals this year, led by its $10 billion buyout of Verona Pharma in July, giving the pharma ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.

Speaking at a conference this morning, Pfizer CEO Albert Bourla suggested that Metsera’s therapies could begin hitting the ...

Unpredictable communication and a lack of transparency are eroding the industry’s and the public’s trust. The FDA, experts ...

Korro Bio is moving back to square one as a preclinical biotech after the failure of KRRO-110 in alpha-1 antitrypsin ...

The decision to pause dapiglutide will help Zealand focus investment into assets that have “the greatest potential for ...

In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial ...

Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes ...